Conor Medsystems (Menlo Park, California) presented acute and follow-up data from the PISCES (Paclitaxel In-Stent Controlled Elution Study) trial during last month’s EuroPCR (previously Paris Course on Revascularization) conference in Paris. The company said results from the trial support the safety of its stents and demonstrated in one of the study arms a binary restenosis rate of 0%.